Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration

J Neurosci. 2002 Jun 15;22(12):4942-54. doi: 10.1523/JNEUROSCI.22-12-04942.2002.

Abstract

The primate striatum contains tyrosine hydroxylase (TH)-immunoreactive (ir) neurons, the numbers of which are augmented after dopamine depletion. Glial cell line-derived neurotrophic factor (GDNF) strongly modulates the viability and phenotypic expression of dopamine ventral mesencephalic neurons. The effect of GDNF on TH-ir neurons intrinsic to the striatum has yet to be investigated. In the present study, stereological counts of TH-ir striatal neurons in aged and parkinsonian nonhuman primates revealed that GDNF delivered via a lentiviral vector (lenti-) further increased the number of these cells. Aged monkeys treated with lenti-GDNF displayed an eightfold increase in TH-ir neurons relative to lenti-beta-galactosidase-treated monkeys. Unilateral 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine treatment alone in young monkeys resulted in a bilateral eightfold increase in TH-ir striatal cells. This effect was further magnified sevenfold on the side of lenti-GDNF treatment. These cells colocalized with the neuronal marker neuronal-specific nuclear protein. Some of these cells colocalized with GDNF-ir, indicating that an alteration in phenotype may occur by the direct actions of this trophic factor. Thus, GDNF may mediate plasticity in the dopamine-depleted primate brain, which may serve to compensate for cell loss by converting striatal neurons to a dopaminergic phenotype.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • Aging
  • Animals
  • Antiparkinson Agents / metabolism*
  • Cell Count
  • Corpus Striatum / cytology*
  • Corpus Striatum / drug effects
  • Corpus Striatum / enzymology
  • Dopamine / metabolism*
  • Dopamine Agents / pharmacology
  • Fluorescent Antibody Technique
  • Genetic Therapy
  • Genetic Vectors
  • Glial Cell Line-Derived Neurotrophic Factor
  • Haplorhini
  • Lentivirus / genetics
  • Microscopy, Fluorescence
  • Nerve Growth Factors*
  • Nerve Tissue Proteins / genetics*
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / enzymology
  • Parkinson Disease / enzymology
  • Parkinson Disease / pathology*
  • Parkinson Disease / therapy
  • Substantia Nigra / cytology*
  • Substantia Nigra / drug effects
  • Substantia Nigra / enzymology
  • Tyrosine 3-Monooxygenase / analysis
  • Tyrosine 3-Monooxygenase / immunology

Substances

  • Antiparkinson Agents
  • Dopamine Agents
  • Glial Cell Line-Derived Neurotrophic Factor
  • Nerve Growth Factors
  • Nerve Tissue Proteins
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase
  • Dopamine